Skip to main content

Table 2 Main chromosomal aberrations detected in BRCA1 -mutated TNBC

From: Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer

  

BRCA1-mutated

BRCA1-non-mutated

Chromosomes

Cytobandes

Gains, %

Losses, %

Gains, %

Losses, %

chr5

q14.3 - q21.2

0.36

43.48

0.00

15.08

chr5

q23.1

0.00

39.13

0.00

14.29

chr7

p22.1

26.09

13.04

4.76

11.91

chr8

q24.3

82.61

4.35

57.14

9.52

chr11

p15.5

26.09

8.70

4.76

47.62

chr11

q24.3

4.35

26.09

19.05

4.76

chr12

p12.1

8.70

34.78

47.62

14.29

chr12

q21.33

0.00

39.13

4.76

9.52

chr15

q22.31

26.09

13.04

4.76

14.29

chr15

q24.1 - q24.2

23.92

16.67

2.38

33.33

chr16

q24.3

32.29

13.04

9.52

41.50

chr17

q24.1

39.13

4.35

14.29

4.76

chr17

q24.3

35.87

0.00

9.52

4.76

chr17

q25.1 - q25.3

58.95

3.59

25.12

21.63

chr18

q12.1

10.87

28.26

15.48

4.76

chr18

q12.3

0.00

42.03

0.00

14.29

chr19

q13.2

21.74

4.35

0.00

42.86

chr19

q13.33

21.74

8.70

0.00

42.86

chr19

q13.42

26.09

17.39

4.76

38.10

chr22

q12.3

49.28

11.59

11.91

30.16

chr22

q13.1

50.79

11.07

19.70

33.33

  1. Significant aberrations (P-value ≤0.05) with a variation of gains or losses between BRCA1-mutated and non-mutated triple-negative breast cancer (TBNC) of at least 20% are indicated.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us